Phase 3 Trial of Potential PTSD Treatment Halted

By July 27, 2018

Participants in the trial were randomized to receive Tonmya 5.6mg sublingually at bedtime for 12 weeks or placebo sublingual tablets.

Various PTSD Treatments Evaluated in Updated Review

By May 25, 2018

To update a previous review, researchers searched various databases from May 2012 to September 2017 to identify studies comparing the safety and efficacy of various PTSD interventions.

MDMA-Assisted Psychotherapy Reduces PTSD Symptoms

May 03, 2018

MDMA-assisted psychotherapy effective, well tolerated for veterans and first responders with PTSD

Prazosin Ineffective for Alleviating PTSD-Related Nightmares, Says Study

February 08, 2018

For veterans with chronic PTSD, no significant difference in distressing dreams, sleep quality

FDA Greenlights MDMA Studies for Posttraumatic Stress Disorder

By August 31, 2017

"Our Phase 2 data was extremely promising with a large effect size, and we are ready to move forward quickly," said Amy Emerson, Executive Director of the MAPS Public Benefit Corporation.